Display options
Cite
Harada S, Yanagisawa M, Kaneko S, et al. Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model. Mol Clin Oncol. 2015;3(5):987-994doi: 10.3892/mco.2015.609.
Harada, S., Yanagisawa, M., Kaneko, S., Yorozu, K., Yamamoto, K., Moriya, Y., & Harada, N. (2015). Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model. Molecular and clinical oncology, 3(5), 987-994. https://doi.org/10.3892/mco.2015.609
Harada, Suguru, et al. "Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model." Molecular and clinical oncology vol. 3,5 (2015): 987-994. doi: https://doi.org/10.3892/mco.2015.609
Harada S, Yanagisawa M, Kaneko S, Yorozu K, Yamamoto K, Moriya Y, Harada N. Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model. Mol Clin Oncol. 2015 Sep;3(5):987-994. doi: 10.3892/mco.2015.609. Epub 2015 Jul 21. PMID: 26623038; PMCID: PMC4534867.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2015 Sep;3(5):987-994. doi: 10.3892/mco.2015.609. Epub 2015 Jul 21.

Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model.

Molecular and clinical oncology

Suguru Harada, Mieko Yanagisawa, Saori Kaneko, Keigo Yorozu, Kaname Yamamoto, Yoichiro Moriya, Naoki Harada

Affiliations

  1. Product Research Department, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa 247-8530, Japan.

PMID: 26623038 PMCID: PMC4534867 DOI: 10.3892/mco.2015.609

Abstract

In the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction cancer, it has been reported that the combination of trastuzumab with capecitabine plus cisplatin, or with 5-fluorouracil (5-FU) plus cisplatin, significantly increased overall survival compared with chemotherapy alone (ToGA trial). In addition, adjuvant therapy with capecitabine plus oxaliplatin (XELOX) improved the survival of patients who received curative D2 gastrectomy (CLASSIC trial). However, the efficacy of the combination of trastuzumab with XELOX for patients with HER2-positive gastric cancer remains unknown. The aim of this study, was to investigate the efficacy of the combination of trastuzumab with XELOX in a HER2-positive human gastric cancer xenograft model. Combination treatment with these three agents (trastuzumab 20 mg/kg, capecitabine 359 mg/kg and oxaliplatin 10 mg/kg), was found to exhibit a significantly stronger antitumor activity in NCI-N87 xenografts compared with either trastuzumab or XELOX alone. In this model, treatment with trastuzumab alone or trastuzumab plus oxaliplatin enhanced the expression of thymidine phosphorylase (TP), a key enzyme in the generation of 5-FU from capecitabine in tumor tissues. In

Keywords: capecitabine; oxaliplatin; thymidine phosphorylase; trastuzumab

References

  1. Lancet. 2007 Jan 6;369(9555):29-36 - PubMed
  2. Biochem Pharmacol. 1998 Apr 1;55(7):1091-7 - PubMed
  3. N Engl J Med. 2008 Jan 3;358(1):36-46 - PubMed
  4. Anticancer Res. 2002 Nov-Dec;22(6B):3589-96 - PubMed
  5. Oncol Rep. 2002 May-Jun;9(3):479-82 - PubMed
  6. Biol Pharm Bull. 1996 Nov;19(11):1407-11 - PubMed
  7. Lancet. 2009 Aug 8;374(9688):477-90 - PubMed
  8. Ann Oncol. 2005 Feb;16(2):273-8 - PubMed
  9. Clin Cancer Res. 2007 Jan 1;13(1):228-33 - PubMed
  10. Cancer Res. 2001 Jun 15;61(12):4744-9 - PubMed
  11. Am J Clin Oncol. 2009 Dec;32(6):559-63 - PubMed
  12. Cancer Sci. 2004 Nov;95(11):851-7 - PubMed
  13. N Engl J Med. 2005 Oct 20;353(16):1673-84 - PubMed
  14. Cancer Chemother Pharmacol. 2006 May;57(5):693-702 - PubMed
  15. Ann Surg Oncol. 2003 Apr;10(3):234-41 - PubMed
  16. Cancer Chemother Pharmacol. 2008 Apr;61(4):623-9 - PubMed
  17. Cancer Res. 1998 Feb 15;58(4):685-90 - PubMed
  18. Clin Cancer Res. 2011 Aug 1;17 (15):5060-70 - PubMed
  19. Nature. 2002 Mar 21;416(6878):279-80 - PubMed
  20. Oncol Rep. 2007 Oct;18(4):775-8 - PubMed
  21. Ann Oncol. 2007 Jun;18(6):977-84 - PubMed
  22. Cancer Res. 2007 Dec 15;67(24):11991-9 - PubMed
  23. Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 - PubMed
  24. Adv Exp Med Biol. 2003;532:253-68 - PubMed
  25. Clin Cancer Res. 1999 Oct;5(10):2948-53 - PubMed
  26. Mol Cancer Ther. 2007 Jul;6(7):2065-72 - PubMed
  27. Cancer Immunol Immunother. 2009 Nov;58(11):1887-96 - PubMed
  28. Lancet. 2012 Jan 28;379(9813):315-21 - PubMed
  29. Br J Cancer. 2006 Jan 30;94(2):259-67 - PubMed
  30. Anticancer Drugs. 2008 Sep;19(8):825-31 - PubMed
  31. J Clin Oncol. 2008 Apr 10;26(11):1789-96 - PubMed
  32. Dig Surg. 2007;24(2):101-7 - PubMed
  33. Clin Cancer Res. 1998 Apr;4(4):1013-9 - PubMed
  34. N Engl J Med. 2001 Sep 6;345(10):725-30 - PubMed
  35. Cancer Chemother Pharmacol. 2000;45(4):291-7 - PubMed
  36. Oncol Rep. 2013 Feb;29(2):451-8 - PubMed
  37. Int J Oncol. 2000 Jul;17(1):33-8 - PubMed
  38. Mol Pharmacol. 2000 Nov;58(5):920-7 - PubMed
  39. Int J Cancer. 1999 Sep 24;83(1):127-34 - PubMed
  40. Int J Oncol. 2001 Oct;19(4):717-22 - PubMed
  41. Cancer Chemother Pharmacol. 2007 May;59(6):795-805 - PubMed
  42. N Engl J Med. 2006 Jul 6;355(1):11-20 - PubMed
  43. Lancet. 2010 Aug 28;376(9742):687-97 - PubMed
  44. J Clin Oncol. 2009 Dec 1;27(34):5838-47 - PubMed
  45. Eur J Cancer. 2002 Dec;38(18):2375-81 - PubMed

Publication Types